Phase 1 Study of ABBV-722 Shows Focus on Safety and Pharmacokinetics
AbbVie is conducting Phase 1 study to assess the safety, tolerability, and pharmacokinetics of ABBV-722 in healthy adults.
Asset / Drug
Drug and asset intelligence for ABBV-722 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.